The Board of Pharmacy has received notice of the following product recall. The Board strongly encourages pharmacies to immediately review their quality assurance and recall policies and procedures to determine if any corrective action is required.

NDC	Lot#	Exp. Date	Strength	Size
0703-4004-01	31328184C	11/2021	5 mg/mL	1X5.5ML
0703-4004-01	31327686C	08/2021	5 mg/mL	1X5.5ML
0703-4004-01	31327685C	08/2021	5 mg/mL	1X5.5ML

Teva Pharmaceuticals USA Inc. is recalling the above lots of **Romidepsin Injection** to the **RETAIL** level. The lots were distributed under the Teva Pharmaceuticals USA Inc. label. This recall is being initiated because lot 31328184C did not meet the specification for Impurities during stability testing. The other two lots in the recall had an out of trend result for Impurities and may not meet specification by the end of shelf life. The health hazard assessment and toxicological evaluation concludes that the exposure to the affected product should not pose any adverse health consequences. Furthermore, to date Teva has not received any adverse event reports or product complaints for these three lots.